1. [OP.1B.05] CEREBROPROTECTIVE EFFECT OF AN ANGIOTENSIN TYPE 2 RECEPTOR AGONIST DELIVERED VIA THE INTRANASAL ROUTE AFTER STROKE. (September 2017) Authors: Sumners, C.; Bennion, D.; Jones, C.; Dang, A.; Isenberg, J.; Graham, J.; Waters, M.; Steckelings, U. Journal: Journal of hypertension Issue: Volume 35(2017)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. [PP.02.17] SUCCESSFUL COMPLETION OF A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, SINGLE ASCENDING DOSE TRIAL FOR THE FIRST IN CLASS ANGIOTENSIN AT2-RECEPTOR AGONIST COMPOUND 21. (September 2017) Authors: Steckelings, U.; Lindblad, L.; Leisvuori, A.; Lovro, Z.; Vainio, P.; Graens, J.; Dahlof, B.; Jansson, P.; Unger, T.; Wiksten, A.; Korhonen, P.; Scheinin, M. Journal: Journal of hypertension Issue: Volume 35(2017)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0070 A Nonpeptide AT2 Receptor Agonist Suppresses the Development of Collagen-Induced Arthritis by Upregulation of FoxP3+ Regulatory T Cells. (23rd January 2014) Authors: Sehnert, B.; Schett, G.; Valero-Esquitino, V.; Voll, R.; Steckelings, U. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A187 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗